Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

NCT01114555 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: Bevacizumab, Irinotecan and Temozolomide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]